Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

Researchers have uncovered another piece of the Parkinson’s disease puzzle, identifying that particular immune cells are ...

SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

A novel screening method for Parkinson’s disease (PD) analyzes the volatile compounds in ear wax to detect early signs of the ...

Researchers in East London found that South Asian and Black Parkinson’s disease patients experience more severe motor and ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

When 64-year-old MBK Nair first noticed a subtle tremor in his right hand in 2020, he brushed it off as fatigue or muscle weakness, assuming that could be a sig ...

Differences in the chemicals people's bodies produce - which some people can even smell - may help detect the disease much ...